Symbol="TARS"
AssetType="Common Stock"
Name="Tarsus PharmaceuticalsÂ Inc"
Description="Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California."
CIK="1819790"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="15440 LAGUNA CANYON ROAD, IRVINE, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="565896000"
EBITDA="-95262000"
PERatio="None"
PEGRatio="None"
BookValue="5.49"
DividendPerShare="0"
DividendYield="0"
EPS="-3.55"
RevenuePerShareTTM="0.467"
ProfitMargin="0"
OperatingMarginTTM="-7.66"
ReturnOnAssetsTTM="-0.271"
ReturnOnEquityTTM="-0.493"
RevenueTTM="12500000"
GrossProfitTTM="-17763000"
DilutedEPSTTM="-3.55"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="3.638"
AnalystTargetPrice="45.57"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="24.75"
PriceToBookRatio="2.038"
EVToRevenue="12.78"
EVToEBITDA="-3.446"
Beta="0.695"
num_52WeekHigh="25.25"
num_52WeekLow="11.33"
num_50DayMovingAverage="18.4"
num_200DayMovingAverage="16.04"
SharesOutstanding="32616500"
DividendDate="None"
ExDividendDate="None"
symbol="TARS"
open="17.49"
high="17.56"
low="17.22"
price="17.40"
volume="166815.00"
latest_trading_day="2023-08-24"
previous_close="17.35"
change="0.05"
change_percent="0.2882%"
aroon_positive_momentum_days="75"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="75"
Volume_recent_avg="325760"
Change_recent_avg="0.06"
Delta_recent_avg="0.89"
Variance_recent_avg="0.44"
Change_ratio_recent_avg="0.25"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="75"
Aroon_momentum_negative="25"
image_negative_thumbnail_id_1="126"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0050.jpeg"
image_negative_thumbnail_id_2="500"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0105.jpeg"
image_neutral_thumbnail_id_1="566"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0033.jpeg"
image_neutral_thumbnail_id_2="529"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0070.jpeg"
image_positive_thumbnail_id_1="657"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0051.jpeg"
image_positive_thumbnail_id_2="615"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0093.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1187"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0021.jpeg"
